Abstract
The incidence of skin melanoma is growing globally and in Russia. Also, the proportion of patients with advanced skin melanoma prevails. Introduction into clinical practice of a novel group of immunological drugs (anti-CTLA4 and anti-PD-1) for metastatic melanoma increased the time to disease progression and patients' life expectancy. Prolgolimab is a PD-1 inhibitor, a new domestic drug that is effective and safe in treating metastatic melanoma. The article presents authors' experience with prolgolimab. When used in the first-line treatment of metastatic melanoma, this drug achieved long-term stabilization of the disease. The drug showed good tolerability, including in patients with severe comorbidity.
Reference13 articles.
1. Melanoma epidemiology, biology and prognosis
2. The Global Cancer Observatory. December, 2020. Available at: https://gco.iarc.fr/today/fact-sheets-cancers. Accessed: 05.08.2023.
3. Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019 [Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2018 godu. Pod red. AD Kaprina, VV Starinskogo, GV Petrovoi. Moscow: MNIOI im. P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii, 2019 (in Russian)].
4. Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献